Standard BioTools Inc. (LAB) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Standard BioTools Inc. (LAB) Healthcare & Pipeline Overview

Standard BioTools Inc. provides advanced tools for proteomics and genomics research, serving academic, clinical, and biopharmaceutical sectors. Their platforms, including SomaScan and CyTOF, enable high-throughput analysis of proteins and genes, positioning them as a key player in the medical devices industry with a focus on research applications.

What Is the Investment Thesis for LAB?

Standard BioTools Inc. presents a notable research candidate within the medical devices sector. With a market capitalization of $253M and a P/E ratio of 4.9, the company demonstrates significant earnings potential. The company's gross margin of 51.9% indicates efficient operations and strong pricing power. Growth catalysts include the increasing adoption of proteomics and genomics technologies in drug discovery and personalized medicine. The company's innovative platforms, such as SomaScan and CyTOF, provide a competitive edge. However, potential risks include competition from other medical device companies and the need for continuous innovation to maintain market relevance. The company's beta of 1.42 suggests higher volatility compared to the market.

Based on FMP financials and quantitative analysis

LAB Key Highlights

Market Cap of $253M reflects the company's current valuation in the medical devices market.

• P/E ratio of 4.9 indicates a potentially undervalued stock relative to its earnings.
• Profit Margin of 119.1% demonstrates strong profitability and efficient cost management.
• Gross Margin of 51.9% highlights the company's ability to maintain profitability after accounting for the cost of goods sold.
• Beta of 1.42 suggests the stock is more volatile than the market, potentially offering higher returns but also higher risk.

Who Are LAB's Competitors?

LAB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LAB's Key Strengths?

Innovative technology platforms (SomaScan, CyTOF).

• Strong intellectual property portfolio.
• Established customer base in academia and biopharma.
• High profit margin of 119.1%.

What Are LAB's Weaknesses?

Reliance on research and development spending.

• Competition from larger medical device companies.
• Potential for product obsolescence.
• Beta of 1.42 indicates higher volatility.

What Could Drive LAB Stock Higher?

Increasing adoption of proteomics and genomics technologies in drug discovery.

• Expansion of the SomaScan platform into new applications.
• Potential for new product launches in the next 12-18 months.
• Strategic partnerships and acquisitions to expand market reach.
• Increasing investments in healthcare and research in the Asia Pacific region.

What Are the Key Risks for LAB?

Financial-distress signal — its Altman Z-Score of -0.31 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-20.8%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 8 reported quarters.
• Economic downturns affecting research funding.
• Regulatory changes impacting the medical device industry.
• Emergence of disruptive technologies.
• Competition from larger medical device companies.
• Reliance on research and development spending.

What Are the Growth Opportunities for LAB?

• Expansion of SomaScan Platform: The SomaScan platform, which enables simultaneous protein measurement, presents a significant growth opportunity. The market for protein analysis is expanding rapidly, driven by the increasing demand for personalized medicine and drug discovery. Standard BioTools can leverage this trend by expanding the applications of the SomaScan platform and targeting new customer segments, such as clinical diagnostics. This expansion could potentially increase revenue by 20% within the next three years.
• Increased Adoption of CyTOF Technology: The CyTOF technology platform, which uses metal-tagged antibodies for enhanced multiplexing, offers a competitive advantage in the field of cell analysis. The market for cell analysis is growing due to the increasing focus on immunotherapy and cancer research. Standard BioTools can capitalize on this trend by promoting the benefits of CyTOF technology and expanding its customer base in the biopharmaceutical sector. Increased adoption of CyTOF could lead to a 15% increase in revenue over the next two years.
• Geographic Expansion in Asia Pacific: The Asia Pacific region represents a significant growth opportunity for Standard BioTools, driven by the increasing investments in healthcare and research. The company can expand its presence in this region by establishing partnerships with local distributors and research institutions. This geographic expansion could result in a 10% increase in overall revenue within the next five years.
• Development of New Consumables: Consumables represent a recurring revenue stream for Standard BioTools. The company can drive growth by developing new consumables that are compatible with its existing platforms. This includes developing new reagents, antibodies, and assays that enhance the capabilities of its instruments. The introduction of new consumables could contribute to a 5% increase in annual revenue.
• Strategic Partnerships and Acquisitions: Standard BioTools can accelerate its growth by forming strategic partnerships with other companies in the life sciences industry. This includes partnering with companies that offer complementary technologies or services. The company can also consider acquiring smaller companies with innovative technologies to expand its product portfolio. Strategic partnerships and acquisitions could lead to a 25% increase in market share over the next five years.

What Are LAB's Competitive Advantages?

• Proprietary Technologies: Standard BioTools' SomaScan and CyTOF platforms are protected by patents and offer unique capabilities.
• Established Customer Base: The company has a strong customer base in the academic and biopharmaceutical sectors.
• High Switching Costs: Customers who have invested in Standard BioTools' instruments and software are likely to continue using their products due to the cost and effort of switching to alternative solutions.
• Expertise and Know-How: The company has deep expertise in proteomics and genomics, which is difficult for competitors to replicate.

What Does LAB Do?

Standard BioTools Inc., formerly Fluidigm Corporation, was founded in 1999 and is headquartered in South San Francisco, California. The company develops, manufactures, and sells a range of instrumentation, consumables, and services tailored for scientists and biomedical researchers. Their offerings support the development of therapeutics across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. Standard BioTools operates through two primary segments: Proteomics and Genomics. These segments encompass instruments, consumables, software, and services based on technologies used in the identification of proteins, genes, and their functions. Key platforms include the SomaScan platform, which enables simultaneous protein measurement and deep insights into biological processes; the CyTOF technology platform, utilizing metal-tagged antibodies for enhanced multiplexing; the Hyperion spatial biology platform, which preserves spatial context for high-dimensional molecular analysis; and the Biomark X9 system, designed for high-throughput genomics in quantitative polymerase chain reaction applications. The company serves academic research institutions, translational research centers, cancer centers, clinical research laboratories, and biopharmaceutical, biotechnology, and plant and animal research companies. Standard BioTools also maintains license agreements with institutions like the California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc.

What Products and Services Does LAB Offer?

• Develops and manufactures instrumentation for proteomics and genomics research.
• Provides consumables, including reagents and assays, for use with their instruments.
• Offers software solutions for data analysis and visualization.
• Delivers services, such as training and support, to customers.
• Provides the SomaScan platform for simultaneous protein measurement.
• Offers the CyTOF technology platform for enhanced multiplexing in cell analysis.
• Provides the Hyperion spatial biology platform for high-dimensional molecular analysis.
• Offers the Biomark X9 system for high-throughput genomics in quantitative polymerase chain reaction applications.

How Does LAB Make Money?

• Sells instruments to academic research institutions, translational research centers, and biopharmaceutical companies.
• Generates recurring revenue through the sale of consumables.
• Provides software and services for data analysis and instrument maintenance.
• Licenses its technologies to other companies.

What Industry Does LAB Operate In?

Standard BioTools Inc. operates in the medical devices industry, which is experiencing growth driven by advancements in genomics and proteomics. The competitive landscape includes companies offering similar technologies for protein and gene analysis. Standard BioTools differentiates itself through its innovative platforms like SomaScan and CyTOF, which offer high-throughput and high-dimensional analysis capabilities. The company's focus on research applications positions it within a niche market segment with significant growth potential.

Who Are LAB's Key Customers?

• Academic research institutions
• Translational research and medicine centers
• Cancer centers
• Clinical research laboratories
• Biopharmaceutical, biotechnology, and plant and animal research companies

Standard BioTools Inc. Financial Trajectory

Standard BioTools Inc. (LAB) reported $20.1M in revenue for Q2 2026, a decline of 4.9% compared to the prior quarter. The company recorded a net loss of $26.8M, with diluted EPS of $-0.07. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, LAB averaged $-0.06 in diluted EPS.

Company Profile

Standard BioTools Inc. operates in the Medical - Equipment & Services industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Michael Egholm. LAB has traded publicly since 2011.

How Standard BioTools Inc. Is Valued

Standard BioTools Inc. carries a market capitalization of $253M, placing it in the micro-cap category. Relative to its peer group, LAB's quantitative score of 16/100 is below the peer average of 79/100.

Return on equity for Standard BioTools Inc. stands at -20.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -14.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -25.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -25.8%, the inverse of the P/E and a quick read on earnings relative to price.

Standard BioTools Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.31 places it in the distress zone, a signal of elevated financial risk.

Standard BioTools Inc. has missed Wall Street's EPS estimate in 2 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 23.8% below estimates on average.

Wall Street analysts project Standard BioTools Inc. revenue of about $82.5M for fiscal 2026, with EPS near $-0.03.

LAB Financials

LAB Latest News

No recent news available for LAB.

LAB Analyst Consensus

LAB MoonshotScore

What Investors Ask About Standard BioTools Inc. (LAB) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources